Journal Club

Background Over nearly 2 decades, tight-control treatment strategies have shown potential to transform management of inflammatory arthritic diseases. By using treatment strategies emphasizing early and tight control of disease activity, along with quantifiable and validated outcome measures, clinicians may limit the extent of disease-related joint damage and preserve patients’ quality of life. In 2004, Grigor…

Background Psoriatic arthritis (PsA) is related to both adverse body composition1 and elevated cardiometabolic risk,2 but these relationships are incompletely understood.3 It is unclear which variables most directly and strongly influence cardiometabolic risk in PsA; this uncertainty prevents systematic and reliable cardiovascular risk prediction for patients with PsA. It is unknown whether global measures of…

Background The introduction of biologics into the treatment of psoriatic arthritis (PsA) has dramatically improved clinical outcomes. Across the approximately 2 decades since the first tumor necrosis factor α (TNF-α) inhibitors were approved in the early 2000s, available drug options for patients with PsA have continued to evolve. In particular, biologics targeting the interleukin 17…

Background Psoriatic arthritis (PsA) is a heterogeneous disease with variable phenotypes.1 Several composite measures have been developed in the past decade to assess disease activity in PsA, but there is no consensus on the best method to accurately assess patients’ overall disease activity and responses to treatment.2,3 Recently, the Group for Research and Assessment of…